ADG-106, a leading product of Tianxing Pharmaceuticals, has been approved for clinical trials issued by China's State Drug Administration

today (November 1), Tianxing Pharmaceuticals announced thatCompany's(the of independently developed leadingproduct
s (the NationalMedicines(The NationalMedicines Administration of China ( the NationalMedicines(The Regulatory Authority issued the ClinicalTrial(approved), and the United States Phase I clinical trial has completed the first patient administrationabout the DG-106it is learned that the DG-106 is derived from the original antibody platform generated for CD137 of the exciting all-human monoclonal antibodyCD137 (or 4-1BB) as a tumor necrosis factor (TNF) receptor superfamily member, has been the focus of attention from all walks of life tumor immunotherapy target, but also clinically proven effective stimulation of T cell hyperplasia of an important channelthe target can induce the activation of CD8-T cells, DC cells, and natural killer (NK) cells by binding to their ligands, thereby enhancing the lethality of cancer cellsAt the same time, the target can also affect T-regulating cells, inhibit autoimmune diseasesThe importance of the4-1BB pathway has also been confirmed in the U.SDrug Enforcement Administration's approved Market Car-T cell therapyThe pharmaceutical industry will study the safety and efficacy of ADG-106 as a singledrug
in Phase I clinical lynx(for patients with solid tumors and non-Hodgkin's lymphoma)about Tianxing PharmaceuticalsTianxing Pharmaceuticals is a "no difficult antibodies in the world" as its mission, committed to building an independent intellectual property rights of the "dynamic precision antibody library" and unique original antibody product line of biological pharmaceutical companiesBased on the original technology platform, the deep layout of tumor immunity and targeted treatment field, with target and antibody technology innovation as the driving force, based on sufficient translational medical data, and strive to achieve product sepsis in clinical efficacy and safety breakthroughat present, Tianxing Pharmaceutical shasted three rounds of financing, raising more than 500 million yuanInvestors include F-Prime Capital (formerly Fidelity Boston Biotech Fund), Stowe Capital Ventures (formerly Fidelity Long Fund), Pharmaceutical Sinkang Venture stake fund, JinpuHealth(Fund and New World Information Technology) and Sequoia China